Indivior Pharmaceuticals, Inc.
INDV
$34.62
-$0.15-0.43%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 8.20% | -11.45% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 8.20% | -11.45% | |||
| Cost of Revenue | 20.00% | -28.57% | |||
| Gross Profit | 6.50% | -8.28% | |||
| SG&A Expenses | 0.00% | -21.29% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.43% | -24.00% | |||
| Operating Income | 10.27% | 9.77% | |||
| Income Before Tax | 39.13% | 41.98% | |||
| Income Tax Expenses | 46.15% | 223.81% | |||
| Earnings from Continuing Operations | 37.08% | -12.75% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 37.08% | -12.75% | |||
| EBIT | 10.27% | 9.77% | |||
| EBITDA | 10.14% | 9.63% | |||
| EPS Basic | 42.85% | -12.48% | |||
| Normalized Basic EPS | 18.88% | 7.09% | |||
| EPS Diluted | 42.03% | -12.64% | |||
| Normalized Diluted EPS | 18.68% | 6.87% | |||
| Average Basic Shares Outstanding | -4.03% | -0.31% | |||
| Average Diluted Shares Outstanding | -3.88% | -0.09% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||